Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
68 results about "Testicular cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cancer that develops in the testicles, a male organ that produce sex hormones and sperm for reproduction.
Biological compositions and methods for treatment of testicular cancer
The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with testicular cancer. The biological compositions can be used to retard the growth of testicular cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.
Owner:ULTRA BIOTECH
Prmt1 for target genes of cancer therapy and diagnosis
InactiveUS20110160293A1Minimal adverse effectEasy to solveCompound screeningOrganic active ingredientsDiseaseOncology
Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.
Owner:ONCOTHERAPY SCI INC
MORC gene compositions and methods of use
InactiveUS6632934B1Easy to storeInhibit microbial growthSugar derivativesAnimals/human peptidesPlant Germ CellsNucleotide
Disclosed are compositions and methods comprising a novel mammalian gene, designated MORC, that is expressed in male germ cells. Also disclosed are polynucleotide compositions comprising a MORC gene from human and murine sources, and polypeptides encoded by these nucleic acid sequences. Methods for preparing MORC polypeptides, transformed host cells, and antibodies reactive with MORC polypeptides are also provided. In certain embodiments, the invention describes methods for diagnosing and treating infertility or testicular cancer, as well as methods for identifying MORC-related polynucleotide and polypeptide compositions.< / PTEXT>
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Soluble Nanoparticles as Delivery Systems for Prodrugs
Compounds and methods are disclosed in which a prodrug can be delivered in an elevated oxidative state to cells by means of graphitic nanoparticles to which the prodrug is attached by a hydrophilic polymer and which have been made soluble by a hydrophilic polymer, such as PEG. The graphitic nanoparticle may be a single walled carbon nanotube (SWNT). The prodrug may be a DNA-binding metal-based drug. Exemplified is a platinum(IV) complex c,c,t-[Pt(NH3)2Cl2(OEt)(O2CCH2CH2CO2H)], which is nearly nontoxic to testicular cancer cells, but displays a significantly enhanced cytotoxicity profile when attached to the surface of amine-functionalized soluble SWNTs. An amine functionality on the hydrophilic polymer may be used to link the prodrug.
Owner:MASSACHUSETTS INST OF TECH +1
Antibodies for treatment of cancer
ActiveUS20140127219A1Minimize adverse effectsHigh levelImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsMelanomaLung cancer
The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
Owner:GANYMED PHARMA AG +1
Biological compositions and methods for treatment of testicular cancer
The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with testicular cancer. The biological compositions can be used to retard the growth of testicular cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.
Owner:ULTRA BIOTECH
Deuterium-Enriched Pyrimidine Compounds and Derivatives
The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.
Owner:DHANOA DALJIT SINGH
Antibodies, pharmaceutical compositions and methods
ActiveUS20180339061A1Effective preventionEffective treatmentOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsSquamous CarcinomasProstate cancer
Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and / or brain tumor.
Owner:OBI PHARMA
Antibodies for treatment of cancer
ActiveUS9321842B2Improve survivalMinimize adverse effectsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsMelanomaLung cancer
Owner:GANYMED PHARMA AG +1
Immunogenic peptides and methods of use
The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.
Owner:UNITED STATES OF AMERICA
Antibodies specific for claudin 6 (CLDN6)
ActiveUS20120308478A1Minimize adverse effectsHigh levelPeptide/protein ingredientsGenetic material ingredientsDiseaseMelanoma
The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
Owner:GANYMED PHARMA AG +1
Antibodies specific for claudin 6 (CLDN6)
ActiveUS20160222125A1Improve survivalMinimize adverse effectsPeptide/protein ingredientsGenetic material ingredientsDiseaseMelanoma
The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
Owner:JOHANNES GUTENBERG UNIV +1
Compounds and methods for modulation of estrogen receptors
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-β over ER-α. Methods are disclosed for modulating ER-β in cell and / or tissues expressing the same, including cells and / or tissue that preferentially express ER-β. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.
Owner:SIGNAL PHARMA LLC
Use of aqueous extract of Trametes robiniophila Murr. in preparing medicament
The invention discloses a usage of Jew ear fungal aqueous extract in the preparation of a drug for curing tumors, wherein, the tumors include cervical cancer, ovarian cancer, carcinoma of endometrium, vulva cancer, prostate cancer, parotid gland, thyroid cancer, salivary gland cancer, skin cancer, nasopharyngeal carcinoma, tongue cancer, oral cavity cancer, carcinoma of larynx, encephaloma, carcinoma of gallbladder, renal carcinoma, gingival carcinoma, testicular cancer, penile cancer, multiple myeloma and / or malignant melanoma.
Owner:QIDONG GAITIANLI MEDICINES
Glutathione derivative and anti-tumor medical application thereof
The invention belongs to the technical field of medicaments, and discloses anti-tumor medicaments of S-(bromo-acetamido-alanyl-methyl) glutathione and S-(bromo-acetamido-butaminoacyl-methyl) glutathione. The compound reacts with aldoketomutase I in a covalent bond mode so that the aldoketomutase I losses the activity irreversibly. The compound has good development and application prospects in theaspects of medicaments for treating the malignant tumors of prostate cancer, lung cancer, intestinal cancer, testicular cancer, leukemia, mammary cancer, skin cancer and the like.
Owner:SHANGHAI YUANNONG MEDICAL SCI
VHZ for diagnosis and treatment of cancers
We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer in an individual selected from the group consisting of: colon cancer, lung cancer, squamous cell carcinoma including lip, larynx, vulva, cervix and penis cancer, pancreatic cancer, brain cancer, oesophageal cancer, stomach cancer, bladder cancer, kidney cancer, skin cancer, ovary cancer, prostate cancer and testicular cancer. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of such a cancer. The anti-VHZ agent may comprise SEQ ID NO:4 or SEQ ID NO: 5, or both.
Owner:AGENCY FOR SCI TECH & RES
(Spirocyclylamido)aminothiophene compounds
Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, R1, X and Y are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis / mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer / T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.
Owner:OSI PHARMA INC
Application of micromolecular nucleic acid miR-302 for treating or preventing testicular cancer
InactiveCN102772806AIncreased sensitivityReduce doseHeavy metal active ingredientsGenetic material ingredientsTreatment effectSide effect
The invention relates to endogenic non-coding microRNA (micro Ribonucleic Acid), a medicine composition containing the microRNA, and new application of the medicine composition for treating or preventing the testicular cancer. According to the invention, the microRNA belonging to the family member (miR-302) of the microRNA-302 and platinum-type anti-tumour medicines are utilized jointly, so that the treatment effect of the platinum-type anti-tumour medicines for the testicular cancer can be obviously improved, and simultaneously, the administration dose, the administration time course and the side effects of the platimun-type anti-tumour medicines can be reduced. The invention also improves a molecular mechanism of the platinum-type anti-tumour medicines for treating the testicular cancer and develops a new treatment target spot for treating the testicular cancer, thereby having a significant value.
Owner:UNIV OF SCI & TECH OF CHINA
Methods and compositions for evaluation of fertility
InactiveUS20050282191A1Reduced fertilityHigh activitySugar derivativesMicrobiological testing/measurementObstetricsPhysiology
The present invention concerns compositions and methods for evaluating fertility in humans and animals. The invention may also be used to identify reproductive cancers such as testicular cancer. In various embodiments of the invention, an Sptrx-3 enzyme is used as a fertility marker. Sptrx-3 may be detected in accordance with the invention in vitro or in vivo.
Owner:UNIVERSITY OF MISSOURI
Compounds and methods for modulation of estrogen receptors
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-β over ER-α. Methods are disclosed for modulating ER-β in cell and / or tissues expressing the same, including cells and / or tissue that preferentially express ER-β. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.
Owner:SIGNAL PHARMA LLC
Method and Kit for Determining Sensitivity to Decitabine Treatment
InactiveUS20130023439A1Nucleotide librariesMicrobiological testing/measurementPlant Germ CellsChemotherapeutic drugs
The present invention is a gene expression panel of chemotherapeutic drug-resistant cancer stem cells comprising RIN1, SOX15 and TLR4. In one embodiment the cancer stem cells are testicular cancer germ cells. The present invention provides for a kit and method for determining response to treatment with decitabine at low doses.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Compositions for Inhibiting Growth of Cancer Stem Cells
InactiveUS20120156312A1Restore sensitivityHeavy metal active ingredientsBiocidePlant Germ CellsOncology
The present invention is a biomarker of chemotherapeutic drug-resistant cancer stem cells and a method of inhibiting the growth of drug-resistant cancer stem cells. In one embodiment the cancer stem cells are testicular cancer germ cells. In another embodiment the present invention is a method of overcoming drug resistance in cancer treatment where the combination of low dose decitabine and administration of a chemotherapeutic drug to which cancer cells were resistant results in successful cancer treatment.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Alkylsulphonamide quinolines
InactiveCN101370782AImprove solubilityPromote absorptionNervous disorderOrganic chemistryDiseaseQuinoline
The invention discloses compounds of Formula (1), pharmaceutically-acceptable salts, methods of making them, pharmaceutical compositions containing them and methods for their use. The compounds are neurokinin-3(NK-3) receptor antagonists and are used in the treatment of diseases such as depression, anxiety, schizophrenia, cognitive disorders, psychoses, obesity, inflammatory diseases, irritable bowel syndrome, inflammatory bowel disorder, emesis, preeclampsia, chronic obstructive pulmonary disease, disorders associated with excessive gonadotrophins and / or androgens including dysmenorrhea, benign prostatic hyperplasia, prostatic cancer and testicular cancer.
Owner:ASTRAZENECA AB
Methods and Kits for Detecting Germ Cell Genomic Instability
Disclosed are methods for detecting microsatellite instability in the germ line of males, methods of assessing risk for developing testicular cancer, methods of evaluating the microsatellite stability of putative cancer or precancerous cells or a tumor, methods for evaluating germ cells for exposure to mutagens, and kits for use in the methods of the invention.
Owner:PROMEGA CORP
Methods and compounds for modulating male fertility
The invention features methods and reagents useful for the treatment of excessive or insufficient apoptosis in cells, and, particularly, in germ-line cells. The invention is useful in treating testicular cancers, cancers of germ-line cells, cancers in non-germ-line cell tissues, infertility (e.g., male infertility), and for birth control (e.g., male birth control).
Owner:UNIVERSITY OF OTTAWA
RBM3 in Testicular Cancer Diagnostics and Prognostics
InactiveUS20120040338A1Organic active ingredientsTumor rejection antigen precursorsTesticleTesticular cancer
The present disclosure provides a method for determining whether a mammalian subject belongs to a first or a second group, wherein subjects of the first group have a higher risk of having a testicular disorder than subjects of the second group, comprising the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA in at least part of an earlier obtained sample comprising biological material from a testicle of said subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group. Further, a prognostic method for testicular cancer is provided, as well as means and uses with prognostic and diagnostic applications.
Owner:ATLAS ANTIBODIES
Application of proguanil to preparation of anti-tumor drug
ActiveCN108030777APowerful tumor suppressor effectPrevent effectOrganic active ingredientsAntineoplastic agentsProstate cancerLung cancer
The invention discloses application of proguanil to preparation of an anti-tumor drug and application of proguanil to preparation of a drug for inhibiting primary tumor growth and / or metastatic tumorgrowth; a tumor is a malignant tumor or a benign tumor, wherein the malignant tumor comprises one or more of a bladder tumor, melanoma, mastadenoma, non-Hodgkin's lymphoma, a colorectal cancer, a pancreatic cancer, an endometrial cancer, a prostate cancer, renal carcinoma, renal cell carcinoma, a non-melanoma skin cancer, leukemia, a thyroid cancer, a lung cancer, a cervical cancer, an ovarian cancer, a testicular cancer and a central nervous system tumor; the drug is a proguanil single component or a pharmaceutical composition containing an effective dose of proguanil, a drug mixture or a molecular structure modifier. Study results show that the proguanil realizes a strong anti-cancer effect by key protein AMPK in targeting tumor cell energy metabolism, and the effect of the proguanil ontumor treatment is stronger than that of N-(4-fluorophenyl) biguanidine, metformin and other biguanidine drugs.
Owner:HUNAN NORMAL UNIVERSITY
(Arylamidoaryl)squaramide compounds
Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R5, m and J are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis / mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer / T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.
Owner:OSI PHARMA INC
Purpose of pyrazolopyrimidine derivative for preparation of medicine for treating diseases
PendingCN109549941AEnhanced inhibitory effectExcellent inhibitory effectOrganic active ingredientsAntineoplastic agentsDiseaseProstate cancer
The invention relates to the technical field of a medicine, and especially relates to a purpose of pyrazolopyrimidine derivative for preparation of medicine for treating diseases. The diseases includemyelodysplastic syndrome, ovarian cancer, testicular cancer, skin squamous cell carcinoma, bladder cancer, cancer of biliary duct, prostate cancer, glioma, nasopharyngeal carcinoma, renal cancer, tongue squamous carcinoma, squamous cell lung carcinoma, maxicell lung cancer, renal cell adenocarcinoma, choriocarcinoma, and placental villus cancer. The pyrazolopyrimidine derivative of the inventionhas obvious inhibitory effects on various tumor cells, especially the tumor cell inhibiting effect of glioma, and the inhibition effect on some tumor cells is better than that of sorafenib.
Owner:GUANGXI WUZHOU PHARMA GRP
Water-soluble fullerene nano-material and preparation method and applications thereof
ActiveCN108478598AHigh suppression efficiencyLow costCarbon active ingredientsPharmaceutical non-active ingredientsSolubilityDisease
The invention discloses a water-soluble fullerene nano-material and a preparation method and applications thereof. The general structural formula of the water-soluble fullerene nano-material is C<2n>(OH)<x>(Amino Acid)<y>, wherein 20 <= n <= 60, 0 <= x < 50, 0 <= y < 20, and the Amino Acid is a water-soluble amino acid. The water-soluble fullerene nano-material can be applied to prepare medicinesof tumour treatment, the tumour is at least one kind of the following diseases: liver cancer, lung cancer, colorectal cancer, kidney cancer, pancreatic cancer, osteocarcinoma, mammary cancer, ovariancancer, prostatic cancer, esophageal cancer, gastric cancer, oral cancer, nasal cancer, laryngocarcinoma, cholangiocarcinoma, cervical carcinoma, uterine cancer, testicular cancer, meningioma, skin cancer, melanoma and sarcoma. The material has good water solubility and good endophilicity with organisms, and can obviously block tumor vessels and rapidly cut off nutritional supply of tumor tissues;and the material is low in preparation costs.
Owner:BEIJING FUNAKANG BIOTECH CO LTD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com